Eastern Bankshares Inc. Common Stock vs McKesson Corporation — how do they compare? Eastern Bankshares Inc. Common Stock trades at $20.77 (market cap $4.79B), while McKesson Corporation trades at $983.95 (market cap $112.15B). The key difference: McKesson Corporation is far larger — about 23.4× Eastern Bankshares Inc. Common Stock's market cap, and Eastern Bankshares Inc. Common Stock pays the higher dividend (2.67%). Which is the better fit depends on your goals — on Pluang, investors hold Eastern Bankshares Inc. Common Stock for 0 Days and McKesson Corporation for 74 Days on average.
| EBC | MCK | |
|---|---|---|
Market Cap | $4.79B | $112.15B |
Volume | 1,740,716 | 743,618 |
Sector | Financials | Health |
52-Week High | $23.65 | $995.69 |
52-Week Low | $16.73 | $725.17 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $5.07B | $118.68B |
Dividend Yield | 2.67% | 0.39% |
Signals from Pluang's Aura AI — not financial advice
Eastern Bankshares (EBC) trades at $20.96, down 0.85% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.71, net income margin of 33.47%, and recent Q2 2026 EPS beat. Analyst consensus is bullish with a $25.60 price target. Recent news highlights institutional buying and upcoming Q3 2026 earnings.
The outlook is positive given solid profitability, attractive valuation, and analyst support. Key risks include integration challenges from recent acquisitions and interest rate sensitivity. Upside potential exists if earnings momentum continues, but investors should monitor net cash flow trends and competitive pressures.
McKesson Corporation (MCK) trades at $976.57, up 2.18% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth from $309B to $359B annually. Recent news highlights the CVS Health partnership extension through 2032, reinforcing distribution stability. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $978.
Outlook remains positive given earnings momentum and strategic partnerships, though valuation at 25.8x P/E and thin 1.12% net margins pose risks. Analysts maintain 80.65% buy ratings with $956 consensus target, slightly below current price. Key risks include drug pricing pressure and macroeconomic sensitivity. Institutional accumulation supports medium-term upside if execution continues.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Eastern Bankshares, Inc. is the holding company for Eastern Bank, a Massachusetts-based bank operating more than 125 branches across eastern Massachusetts, southern and coastal New Hampshire, and Rhode Island, offering consumer and business banking along with wealth management through its Cambridge Trust divisions.
Read more on EBC →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →